-
Fultagliptin Benzoate Tablets Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Fultagliptin Benzoate Tablets (trade name: 信立汀) of Shenzhen Salubris Pharmaceuticals Co., Ltd. is approved by China NMPA.
-
Fulzerasib Tablets Approved with Conditions for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Fulzerasib Tablets (trade name:达伯特) of Innovent Biologics, Inc. is approved with condition for marketing through the priority review and approval procedure by China NMPA.
-
NMPA Re-elected as a Member of the ICH Management Committee
2025-02-19
On June 4, 2024, the plenary session of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) was held in Fukuoka, Japan, at which the National Medical Products Administration (NMPA) was elected as a member of the ICH Management Committee for the third time.
-
Rezivertinib Mesylate Capsules approved for marketing by China NMPA
2024-05-20
Recently, the Class 1 innovative drug Rezivertinib Mesylate Capsules (trade name: 瑞必达) of Beta Pharma (Shanghai) Co., Ltd. is approved for marketing by China NMPA.
-
Crisugabalin Besilate Capsules approved for marketing by China NMPA
2024-05-20
Recently, the Class 1 innovative drug Crisugabalin Besilate Capsules (trade name: 思美宁) of Haisco Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for adult patients with diabetic peripheral neuropathic pain.
-
Repotrectinib capsules approved with conditions for marketing by China NMPA
2024-05-11
Recently, the Class 1 innovative drug Repotrectinib Capsules (trade name: 奥凯乐/AUGTYRO) of Bristol-Myers Squibb Company is approved for marketing with conditions through the priority review and approval procedure by China NMPA.
